X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs ALEMBIC PHARMA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH ALEMBIC PHARMA STERLING BIOTECH/
ALEMBIC PHARMA
 
P/E (TTM) x -0.4 18.2 - View Chart
P/BV x 0.0 4.6 0.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 STERLING BIOTECH   ALEMBIC PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
ALEMBIC PHARMA
Mar-18
STERLING BIOTECH/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs11645 1.6%   
Low Rs3470 0.7%   
Sales per share (Unadj.) Rs26.8166.1 16.1%  
Earnings per share (Unadj.) Rs-15.021.9 -68.3%  
Cash flow per share (Unadj.) Rs-5.527.5 -19.9%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs54.9117.8 46.6%  
Shares outstanding (eoy) m267.87188.52 142.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 7.7%   
Avg P/E ratio x-0.525.5 -1.8%  
P/CF ratio (eoy) x-1.320.3 -6.3%  
Price / Book Value ratio x0.14.7 2.7%  
Dividend payout %018.3 0.0%   
Avg Mkt Cap Rs m1,862105,090 1.8%   
No. of employees `0001.4NA-   
Total wages/salary Rs m5476,228 8.8%   
Avg. sales/employee Rs Th5,303.3NM-  
Avg. wages/employee Rs Th403.8NM-  
Avg. net profit/employee Rs Th-2,959.0NM-  
INCOME DATA
Net Sales Rs m7,18131,308 22.9%  
Other income Rs m4370 60.6%   
Total revenues Rs m7,22331,378 23.0%   
Gross profit Rs m9476,431 14.7%  
Depreciation Rs m2,5431,055 241.2%   
Interest Rs m4,37734 12,873.8%   
Profit before tax Rs m-5,9315,413 -109.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,204 -159.9%   
Profit after tax Rs m-4,0074,128 -97.1%  
Gross profit margin %13.220.5 64.2%  
Effective tax rate %32.422.2 145.9%   
Net profit margin %-55.813.2 -423.2%  
BALANCE SHEET DATA
Current assets Rs m14,33518,247 78.6%   
Current liabilities Rs m49,80911,235 443.3%   
Net working cap to sales %-494.022.4 -2,205.6%  
Current ratio x0.31.6 17.7%  
Inventory Days Days40386 471.4%  
Debtors Days Days17161 278.1%  
Net fixed assets Rs m55,43220,035 276.7%   
Share capital Rs m268377 71.1%   
"Free" reserves Rs m13,93521,824 63.9%   
Net worth Rs m14,70122,201 66.2%   
Long term debt Rs m9,4785,000 189.6%   
Total assets Rs m73,98839,411 187.7%  
Interest coverage x-0.4160.2 -0.2%   
Debt to equity ratio x0.60.2 286.3%  
Sales to assets ratio x0.10.8 12.2%   
Return on assets %0.510.6 4.7%  
Return on equity %-27.318.6 -146.6%  
Return on capital %-6.419.7 -32.6%  
Exports to sales %25.946.4 55.8%   
Imports to sales %0.210.5 1.6%   
Exports (fob) Rs m1,86014,535 12.8%   
Imports (cif) Rs m123,288 0.4%   
Fx inflow Rs m1,86014,722 12.6%   
Fx outflow Rs m257,026 0.4%   
Net fx Rs m1,8357,696 23.8%   
CASH FLOW
From Operations Rs m1,7193,124 55.0%  
From Investments Rs m-3,148-8,844 35.6%  
From Financial Activity Rs m1,4265,026 28.4%  
Net Cashflow Rs m-3-693 0.5%  

Share Holding

Indian Promoters % 33.9 74.1 45.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 2.9 -  
FIIs % 9.9 9.1 108.8%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 13.9 282.7%  
Shareholders   21,482 49,328 43.5%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Oil Prices, Neogen Chemicals IPO, and Top Stocks in Action Today(Pre-Open)

On Tuesday, share markets in India witnessed most of the selling pressure during closing hours and ended marginally lower after a volatile day of trading.

Related Views on News

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 8-QTR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS